Metraipolis › archive › dc_e577e83a77aa

High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial — Europe PMC PMID:41246460

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41246460
DOI: 10.5588/ijtldopen.25.0120
License (as archived): solo-consultazione
Archived: 2026-11-08T15:46:13.278Z
SHA-256 of the archived text: e4aec2d08210b191bc3e31209856109dcced23a4d614a806917fbbf29f7a8d21
Stable URL of this page: https://metraipolis.com/documento/dc_e577e83a77aa

How to cite

High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial — Europe PMC PMID:41246460 — Europe PMC (en), https://europepmc.org/article/MED/41246460 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e577e83a77aa (Metraipolis archive dc_e577e83a77aa, sha256 e4aec2d08210b191bc3e31209856109dcced23a4d614a806917fbbf29f7a8d21)

BibTeX

@misc{dce577e83a77aa,
  title = {High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial — Europe PMC PMID:41246460},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41246460},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e577e83a77aa; sha256 e4aec2d08210b191bc3e31209856109dcced23a4d614a806917fbbf29f7a8d21},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41246460. Agents can read the archived copy with the MCP tool read_document.